Role of Annexin A1 in Squamous Cell Lung Cancer Progression.
Omar ElakadYuchan LiNatascha GieserSha YaoStefan KüfferMarc HinterthanerBernhard C DannerAlexander von Hammerstein-EquordPhilipp StröbelHanibal BohnenbergerPublished in: Disease markers (2021)
Lung cancer remains the primary cause of cancer-related death worldwide, and its molecular mechanisms of tumor progression need further characterization to improve the clinical management of affected patients. The role of Annexin A1 (ANXA1) in tumorigenesis and cancer progression in general and especially in lung cancer remains to be controversial and seems to be highly tissue specific and inconsistent among tumor initiation, progression, and metastasis. In the current study, we investigated ANXA1 expression in 81 squamous cell lung cancer (SQCLC), 86 pulmonary adenocarcinoma (AC), and 30 small cell lung cancer (SCLC) patient-derived tissue samples and its prognostic impact on patient's survival. Mechanistically, we analyzed the impact of ANXA1 expression on proliferation and migration of SQCLC cell lines using CRISPR-Cas9 and mammalian overexpression vectors. Strong expression of ANXA1 was significantly correlated to longer overall survival only in SQCLC patients (P = 0.019). Overexpression of ANXA1 promoted proliferation in SQCLC cell lines but suppressed their migration, while knockout of ANXA1 promoted cell migration and suppressed proliferation. In conclusion, ANXA1 expression might elongate patients' survival by inhibiting tumor cell migration and subsequent metastasis.
Keyphrases
- poor prognosis
- squamous cell
- end stage renal disease
- cell migration
- small cell lung cancer
- ejection fraction
- crispr cas
- newly diagnosed
- chronic kidney disease
- signaling pathway
- prognostic factors
- patient reported outcomes
- squamous cell carcinoma
- peritoneal dialysis
- cell proliferation
- transcription factor
- mass spectrometry
- long non coding rna
- case report
- radiation therapy
- free survival
- papillary thyroid
- brain metastases